We are live on
!
Find out more
RA
Royce & Associates Portfolio holdings
AUM
$12.4B
1-Year Est. Return
64.17%
This Fund
S&P 500
This Quarter
Est. Return
+4.45%
1 Year Est. Return
+64.17%
3 Year Est. Return
+130.04%
5 Year Est. Return
+162.55%
10 Year Est. Return
+785.5%
AUM
$9.86B
AUM Growth
-$168M
(-1.7%)
Cap. Flow
-$326M
Cap. Flow
% of AUM
-3.31%
Top 10 Holdings %
Top 10 Hldgs %
9.48%
Holding
825
New
63
Increased
274
Reduced
363
Closed
64
Avg Time Held
18.2
quarters
Top 10 Avg Time Held
4.6
quarters
Top 20 Avg Time Held
6.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
J&J Snack Foods
JJSF
|
+$29.7M |
| 2 |
WD-40
WDFC
|
+$28.7M |
| 3 |
CBIZ
CBZ
|
+$27.6M |
| 4 |
Exponent
EXPO
|
+$19.4M |
| 5 |
Andersen Group
ANDG
|
+$19.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$42.3M |
| 2 |
Coherent
COHR
|
+$31.6M |
| 3 |
MKS Inc
MKSI
|
+$31.2M |
| 4 |
Sterling Infrastructure
STRL
|
+$30M |
| 5 |
Installed Building Products
IBP
|
+$28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 25.8% |
| 2 | Technology | 18.79% |
| 3 | Financials | 16.43% |
| 4 | Consumer Discretionary | 12.93% |
| 5 | Healthcare | 9.22% |
Similar funds
JF
WRCM
LC
AIM
SC
ERSOT
BAMF
Royce & Associates's Q4 2025 Portfolio in Review
As of Q4 2025, Royce & Associates held 825 positions worth $9.86B, down 1.7% from $10B the previous quarter. Its ten largest holdings account for 9.5% of the portfolio.
Royce & Associates withdrew a net $326M in Q4 2025, closing 64 positions and reducing 363 holdings. Its most notable exit was Charles River Laboratories, an estimated $13.2M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 26% of assets, up from 26% a quarter earlier, followed by Technology and Financials.
Against the trend, Royce & Associates opened a new position in J&J Snack Foods worth $29.6M.
- Royce & Associates's largest Q4 2025 buy was J&J Snack Foods: 327,501 shares worth $29.6M.
- Royce & Associates added most to WD-40 in Q4 2025, an estimated $28.7M increase.
- Royce & Associates's biggest Q4 2025 reduction was Haemonetics, cutting an estimated $42.3M.
- Royce & Associates fully exited Charles River Laboratories in Q4 2025, selling an estimated $13.2M.
- Royce & Associates's ten largest holdings make up 9.5% of its $9.86B portfolio in Q4 2025.
- Royce & Associates opened 63 new positions and closed 64 in Q4 2025.
- Royce & Associates's portfolio value fell 1.7% quarter-over-quarter to $9.86B.
Based on Royce & Associates's 13F filing for Q4 2025, filed 9 Feb 2026.